Bright Green Corporation (BGXX)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.84 Million USD | -65.34% |
| 2022 | 5.31 Million USD | 696.8% |
| 2021 | -890.37 Thousand USD | -417.61% |
| 2020 | 280.33 Thousand USD | 0.0% |
| 2019 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 419.86 Thousand USD | -15.39% |
| 2024 Q1 | 496.23 Thousand USD | -73.06% |
| 2023 Q3 | 1.52 Million USD | -67.51% |
| 2023 FY | 1.84 Million USD | -65.34% |
| 2023 Q4 | 1.84 Million USD | 20.51% |
| 2023 Q2 | 4.7 Million USD | 0.35% |
| 2023 Q1 | 4.68 Million USD | -11.78% |
| 2022 Q2 | 2.21 Million USD | 966.46% |
| 2022 Q1 | -255.98 Thousand USD | 71.25% |
| 2022 FY | 5.31 Million USD | 696.8% |
| 2022 Q4 | 5.31 Million USD | 424.85% |
| 2022 Q3 | -1.63 Million USD | -173.75% |
| 2021 FY | -890.37 Thousand USD | -417.61% |
| 2021 Q2 | -996.11 Thousand USD | -1074.08% |
| 2021 Q4 | -890.37 Thousand USD | 14.22% |
| 2021 Q3 | -1.03 Million USD | -4.2% |
| 2021 Q1 | 102.26 Thousand USD | -63.52% |
| 2020 Q4 | 280.33 Thousand USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | 280.33 Thousand USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 98.045% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 97.543% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 99.577% |
| Cosmos Health Inc. | 8.59 Million USD | 78.562% |
| Dynavax Technologies Corporation | 106.63 Million USD | 98.273% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 101.408% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 99.574% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 111.78% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 111.78% |
| SCYNEXIS, Inc. | -19.35 Million USD | 109.518% |
| Safety Shot Inc | -2.28 Million USD | 180.623% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 119.531% |
| Alpha Teknova, Inc. | 1.97 Million USD | 6.701% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 99.598% |
| Embecta Corp. | 1.31 Billion USD | 99.86% |
| PainReform Ltd. | -7.95 Million USD | 123.166% |
| Journey Medical Corporation | -9.7 Million USD | 118.969% |
| Procaps Group, S.A. | 242.93 Million USD | 99.242% |
| Theratechnologies Inc. | 24.87 Million USD | 92.595% |
| Harrow Health, Inc. | 116.41 Million USD | 98.418% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 173.084% |
| Biofrontera Inc. | 4.05 Million USD | 54.593% |
| DURECT Corporation | -7.65 Million USD | 124.062% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 105.493% |
| Cronos Group Inc. | -663.32 Million USD | 100.278% |
| OptiNose, Inc. | 58.06 Million USD | 96.828% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 99.705% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 112.639% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 135.513% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 87.732% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 128.96% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -1623.509% |
| Radius Health, Inc. | 359.28 Million USD | 99.487% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -833.894% |
| ProPhase Labs, Inc. | 19.23 Million USD | 90.423% |
| Phibro Animal Health Corporation | 454.84 Million USD | 99.595% |
| Procaps Group S.A. | 242.93 Million USD | 99.242% |
| Alvotech | 1.06 Billion USD | 99.827% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 49.926% |
| Viatris Inc. | 17.13 Billion USD | 99.989% |
| Rockwell Medical, Inc. | 4.45 Million USD | 58.669% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 137.763% |
| SIGA Technologies, Inc. | -148.68 Million USD | 101.239% |
| Tilray Brands, Inc. | 158.97 Million USD | 98.842% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 98.489% |
| Shineco, Inc. | 29.29 Million USD | 93.712% |
| PetIQ, Inc. | 351.93 Million USD | 99.477% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 163.476% |
| Incannex Healthcare Limited | -5.48 Million USD | 133.577% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 98.961% |
| Alimera Sciences, Inc. | 55.3 Million USD | 96.67% |
| Silver Spike Investment Corp. | -32.61 Million USD | 105.647% |
| Assertio Holdings, Inc. | -32.52 Million USD | 105.662% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 223.712% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 136.395% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 138.258% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 122.423% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 56.326% |
| Hempacco Co., Inc. | 13.61 Million USD | 86.473% |
| Talphera, Inc. | -5.72 Million USD | 132.192% |
| Alvotech | 1.06 Billion USD | 99.827% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 74.224% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 101.904% |
| Currenc Group, Inc. | -16.57 Million USD | 111.113% |
| Kamada Ltd. | -46.43 Million USD | 103.967% |
| Indivior PLC | -33.95 Million USD | 105.424% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -606.795% |
| Flora Growth Corp. | -713 Thousand USD | 358.306% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 122.423% |
| Evolus, Inc. | 63.7 Million USD | 97.109% |
| HUTCHMED (China) Limited | -197.45 Million USD | 100.933% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 99.616% |
| Akanda Corp. | 3.9 Million USD | 52.836% |